JUPITER, Fla., March 22, 2013 – Dyadic International, Inc. (OTC Pink: DYAI), announced today that its Vice President General Counsel & Business Development and Secretary, Adam J. Morgan, has resigned in order to accept another position.
Dyadic’s President and Chief Executive Officer, Mark Emalfarb, stated, “On behalf of our management team and Board of Directors, I want to thank Adam for his valuable contributions during a crucial time in the company’s history. We wish him all the best in his new position.”
Adam Morgan commented, “Working closely with Mark and the whole Dyadic team in advancing the markets for the company’s robust technology has been a very rewarding experience. I take great pride in what we have accomplished as a team and my contributions to those results. I am confident in Dyadic’s bright future and will continue to root for its success both as a stockholder and supporter of the company.”
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, bio-based chemicals and biopharmaceutical industries.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are forward- looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Investor Relations: Press and Media Relations:
Gary T. Dvorchak, CFACory Ziskind
Senior Vice PresidentVice President
ICR, LLCICR, LLC
+1 (310) 954-1123+1 (646) 277-1232
Vice President and Chief Financial Officer
+1 (561) 743-8333